#lymsm — Public Fediverse posts

#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

#MEDMASTODON
"The right drug for the right patient" -- the promise of personalized medicine

... but I'm not sure that the study methods are sufficient to justify the conclusions. The reason I'm thankful for peer review.

CD5 Gene Signature Identifies Diffuse Large B-Cell #Lymphomas Sensitive to Bruton's Tyrosine Kinase (BTK) Inhibition

https://pubmed.ncbi.nlm.nih.gov/38079587/

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

#MEDMASTODON

Interest, attitudes, and participation in clinical trials among #lymphoma #patients with online access

Authors: K. Schwartz | Advisors to Patients Against Lymphoma

https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.e19514

#Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

Minimal Residual Disease (MRD) Status Predicts Outcome in Patients With Previously Untreated Follicular #Lymphoma

Just saying: Validating MRD as a biomarker predicting living longer or better (clinical benefit) is needed

... as the standard time to event endpoints (PFS, survival) take many many years to assess for indolent (slow growing) #cancer.

https://pubmed.ncbi.nlm.nih.gov/38096461/

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

Dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in relapsed/refractory mantle cell #lymphoma

Gives hope, but be aware there are many issues (too numerous to mention in a toot) with small single-arm studies, such as how many were relapsed versus refractory, and Quality of Life while on continuous treatment. Let's hope the study team confirms with a larger controlled study.

#MEDMASTODON #lymphoma #Cancer #fedscience
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

CD4+ CAR T-cell expansion is associated with response and therapy-related toxicities in patients with B-cell #lymphomas

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471494/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @[email protected]

Encouraging report for patients with an urgent unmet need.

Clinical efficacy and safety of CAR T-cell therapy for mantle cell #lymphoma with secondary central nervous system involvement

https://pubmed.ncbi.nlm.nih.gov/37584155/

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

A Phase II Randomized Study of Zanubrutinib (oral btk-inhibitor) Plus Obinutuzumab (cd20-directed antibody)

Versus

Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular #Lymphoma

https://pubmed.ncbi.nlm.nih.gov/37506346/

217 patients randomized. Surprising to me. Seems worth a close reading of the full report.

#MEDMASTODON #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

#lymphoma #cancer #MEDMASTODON
@majorajay #lymsm

Pembrolizumab
(pem-broh-LIH-zoo-mab)

... an immune checkpoint inhibitor that binds to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system.

in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis

https://pubmed.ncbi.nlm.nih.gov/37130017/

#MEDMASTODON #cancer

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, [to restore p53 tumor suppressor activity ]

in Patients With Advanced Liposarcoma, Solid Tumors, or #Lymphoma

#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

in a 52-patient study, emotional well-being continues to be an unmet need during active surveillance of patients with indolent NHL (compared to norm general population scores)

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

https://pubmed.ncbi.nlm.nih.gov/36120910/

Three of those four #lymphoma patients achieved a complete response with out-of-commercial specification (OOS) CAR T therapy

Risk factors for OOS were ≥ 4 prior therapies or previous bendamustine exposure.

#MEDMASTODON #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

https://pubmed.ncbi.nlm.nih.gov/36111694/

@thewritertype for me it’s funny because it’s totally true, I fought a cancer battle this year and came out ahead. I’m convinced that epic naps were a significant force in my arsenal complementing the chemo. Along with my sidekick Ruffers. People would call to check in on me and I would reply “meh I’m just laying around here on the couch fighting cancer” 🥲
#lymsm #lymphoma #CancerSucks but #NapsAreGood
#Ruffers

#MedMastodon

Placebo alone is very rarely used as a control in cancer trials (only when watchful waiting is also appropriate).

But it's not uncommon for a cancer study to compare A+B versus A+placebo - when there's *genuine uncertainty* about which intervention is better (equipoise); and when A alone is a standard of care.

@majorajay #lymsm

Related: Objective response rate of placebo in randomized controlled trials of anticancer medicines https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00482-5/fulltext

Incredible to see continuously trending #ASH22 and related hashtags across chats/conferences/diseases/other categories! Stoked to see #lymsm #mmsm #leusm #cardiacpath #path2path #meded #lymphoma in the mix too!

Incredible to see continuously trending #ASH22 and related hashtags across chats/conferences/diseases/other categories! Stoked to see #lymsm #mmsm #leusm #cardiacpath #path2path #meded #lymphoma in the mix too!

#ASH22 Don’t miss this live (oral abstracts) presentation by @[email protected] representing @[email protected] and our collaborative team!

Liquid Bx-based NGS is an alternative to tissue molecular profiling of #lymsm #mmsm and #leusm neoplasms!

🕐10:45 AM
📍ENMCC-208-210
📝Paper 498

#ASH22 Don’t miss this live (oral abstracts) presentation by @[email protected] representing @[email protected] and our collaborative team!

Liquid Bx-based NGS is an alternative to tissue molecular profiling of #lymsm #mmsm and #leusm neoplasms!

🕐10:45 AM
📍ENMCC-208-210
📝Paper 498

#MedMastodon
#ScienceMastodon

As people migrate here and get used to the interface -- Liking Mastodon more each day!

#twitter
I installed Nitter on Firefox to track lymphoma posts on twitter without supporting Musk

What #lymsm looks like on Nitter

Any #lymphoma #lymsm folks pioneering #medmastodon here yet?

#introduction I’m feeling like ol’ Rufferito Bandito doesn’t need any introduction but here’s a bit: we’re fun and gregarious, and wicked smart with a lot of diverse interests and I wear a lot of hats. The most recent hat in my collection is cancer-survivor which basically just means that I’m tired all the time.
I can’t make up my mind… I prefer anonymity online but oh the humanity so here’s a recent selfie.
#shattered #selfie #lymsm #survivor #stupidcancer #lymphoma #cancersucks